Citigroup
TRVI icon

Citigroup’s Trevi Therapeutics TRVI Stock Holding History

Citigroup’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7M Buy
488,496
+411,022
+531% +$7.07M ﹤0.01% 1885
2026
Q2 		$1.44M Sell
77,474
-22,475
-22% -$327K ﹤0.01% 3175
2026
Q1 		$1.19M Sell
99,949
-23,549
-19% -$264K ﹤0.01% 2999
2025
Q4 		$1.55M Buy
123,498
+96,585
+359% +$1.12M ﹤0.01% 2825
2025
Q3 		$246K Sell
26,913
-37,046
-58% -$278K ﹤0.01% 3909
2025
Q2 		$350K Buy
63,959
+10,065
+19% +$62.6K ﹤0.01% 3820
2025
Q1 		$339K Buy
53,894
+6,038
+13% +$28.8K ﹤0.01% 3886
2024
Q4 		$197K Buy
47,856
+5,232
+12% +$16.7K ﹤0.01% 4421
2024
Q3 		$142K Buy
42,624
+29,637
+228% +$88.1K ﹤0.01% 4585
2024
Q2 		$38.7K Buy
12,987
+4,284
+49% +$11.9K ﹤0.01% 4724
2024
Q1 		$30K Buy
8,703
+1,747
+25% +$3.9K ﹤0.01% 4892
2023
Q4 		$9.32K Buy
6,956
+6,913
+16,077% +$10.5K ﹤0.01% 5206
2023
Q3 		$94 Sell
43
-12,355
-100% -$27.9K ﹤0.01% 5422
2023
Q2 		$29.6K Buy
+12,398
New +$31.2K ﹤0.01% 4852
2022
Q3 		– Sell
-1,700
Closed -$5K – 6325
2022
Q2 		$5K Buy
+1,700
New +$4.18K ﹤0.01% 5633

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Harbour Capital Advisors
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return

Citigroup's TRVI Position: Q3 2026 in Review

Citigroup increased its Trevi Therapeutics (TRVI) stake by 531% in Q3 2026, buying an estimated $7.07M and bringing the position to 488,496 shares worth $7M. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

Citigroup first reported a position in TRVI in Q2 2022 and has held it in 15 quarters since. 49 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Citigroup held 488,496 shares of Trevi Therapeutics worth $7M as of Q3 2026.
  • Citigroup bought 411,022 Trevi Therapeutics shares in Q3 2026, an estimated $7.07M.
  • Trevi Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1885 holding.
  • Citigroup first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • 49 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.